177Lu-PSMA-I&T for treatment of metastatic castration-resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers

A Karimzadeh, M Heck, R Tauber, K Knorr… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The aim of this retrospective analysis was to determine prostate-specific antigen (PSA)
response, PSA progression-free survival (PFS), and overall survival (OS) in a large cohort of …

Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy …

I Rauscher, A Karimzadeh, K Schiller… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of 18 F-labeled
PSMA-targeting agents. F-rhPSMA-7.3 is a lead compound that is currently under …

The impact of PSMA PET–based eligibility criteria used in the prospective phase II TheraP trial in metastatic castration-resistant prostate cancer patients undergoing …

A Karimzadeh, M Heck, R Tauber… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has shown encouraging
results for treatment of metastatic castration-resistant prostate cancer (mCRPC) in the …

[HTML][HTML] Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis

D Koehler, S Trappe, F Shenas, A Karimzadeh… - European Journal of …, 2024 - Springer
Purpose To identify reasons for negative histopathology of specimens from prostate-specific
membrane antigen (PSMA) radioguided surgery (PSMA-RGS) in recurrent prostate cancer (…

[HTML][HTML] Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria

D Koehler, M Sauer, A Karimzadeh, I Apostolova… - EJNMMI research, 2022 - Springer
Background PSMA PET/CT is the recommended imaging test in cases with prostate-specific
antigen (PSA) recurrence after primary therapy of prostate cancer (PCa). However, imaging …

Prognostic Role of 68Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy

L Lunger, M Chantadisai, A Karimzadeh… - Journal of Nuclear …, 2023 - Soc Nuclear Med
This study was performed to assess the prognostic utility of conventional biochemical and
imaging response criteria and 68 Ga-PSMA11 PET–adapted or –specific systems regarding …

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T

A Karimzadeh, P Soeiro, B Feuerecker… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The aim of this retrospective analysis was to evaluate health-related quality of life (HRQoL)
for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving …

Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators

…, T Buddenkotte, F Mathies, A Karimzadeh… - Journal of Nuclear …, 2024 - Soc Nuclear Med
This study evaluated the potential to reduce the scan duration in dopamine transporter (DAT)
SPECT when using a second-generation multiple-pinhole (MPH) collimator designed for …

[HTML][HTML] Short post-injection seizure duration is associated with reduced power of ictal brain perfusion SPECT to lateralize the seizure onset zone

A Karimzadeh, K Baradaran-Salimi… - EJNMMI …, 2024 - ejnmmires.springeropen.com
The aim of this study was to assess the impact of the post-injection electrical seizure duration
on the identification of the seizure onset zone (SOZ) in ictal brain perfusion SPECT in …

[HTML][HTML] Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments

…, NJ Wiese, M Warncke, J Tintelnot, A Karimzadeh… - Cancers, 2024 - mdpi.com
Simple Summary Quantitative assessment of the therapy response in oncological patients
undergoing chemo- or immunotherapy is becoming increasingly important not only in the …